SGLT2 inhibitors lead to enhanced AMPK/SIRT1 signaling thus increasing authophagy and tubuloglomerular feedback both underpinning the SGLUTi protective effects on diabetic kidney disease [33]. Here, SLC5A2 is linked to diabetic kidney disease.